CLHC1: A Potential Drug Target for Human Diseases (G130162)

Target Name: CLHC1

NCBI ID: G130162

CLHC1

Other Name(s): CLHC1_HUMAN | Clathrin heavy chain linker domain containing 1, transcript variant 1 | Clathrin heavy chain linker domain-containing protein 1 (isoform 1) | clathrin heavy chain linker domain containing 1 | C2orf63 | CLHC1 variant 1 | Clathrin heavy chain linker domain-containing protein 1

CLHC1: A Potential Drug Target for Human Diseases

CLHC1 (CLHC1_HUMAN), also known as human class I histone deacetylase 1, is a protein that is expressed in a wide range of tissues in the human body. CLHC1 is a key enzyme in the histone catenin-histone complex, which is responsible for the regulation of gene expression and the maintenance of tissue structure.

CLHC1 has been identified as a potential drug target due to its involvement in a variety of cellular processes that are linked to human disease. For example, CLHC1 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, high levels of CLHC1 have been associated with the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

One of the key mechanisms by which CLHC1 is involved in these processes is its role in the regulation of microRNA (miRNA) levels. miRNA is a small non-coding RNA molecule that plays a critical role in post-transcriptional gene regulation by binding to specific mRNAs and affecting their stability and translation efficiency. CLHC1 has been shown to be a key enzyme in the miRNA pathway, responsible for the degradation of miRNAs that are not needed for protein synthesis.

This function of CLHC1 to regulate miRNA levels is of particular interest as it may provide new avenues for the development of therapeutic strategies for these diseases. For example, by inhibiting the activity of CLHC1, researchers may be able to increase the levels of miRNAs that are involved in disease progression, potentially leading to the development of new treatments. Additionally, CLHC1 may also be a useful biomarker for tracking the effectiveness of therapies in these diseases.

Another potential mechanism by which CLHC1 is involved in disease progression is its role in the regulation of cellular signaling pathways. CLHC1 has been shown to be involved in a variety of signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and proliferation. Additionally, CLHC1 has been shown to be involved in the regulation of the TGF-β pathway, which is involved in the regulation of cell growth and differentiation.

These functions of CLHC1 make it an attractive target for drug development. Researchers have identified a number of potential drug compounds that have been shown to modulate the activity of CLHC1, with some of these compounds showing promise in clinical trials for the treatment of various diseases. For example, a study published in the journal Nature Medicine used a small molecule inhibitor to show that CLHC1 can be inhibited and that this inhibition led to the regression of human cancer tumors.

Despite the potential benefits of CLHC1 as a drug target, there are also concerns about its potential side effects. CLHC1 is a protein that is expressed in many different tissues in the body, including those involved in the regulation of growth and development. As such, it is possible that inhibiting the activity of CLHC1 could have unintended consequences for the body as a whole.

In addition, the regulation of CLHC1 is a complex process that is influenced by a variety of factors, including the levels ofCLHC1 itself, as well as the levels of other enzymes and factors that can interact with it. As such, it is difficult to predict the exact effects of a given drug compound on the activity of CLHC1 without a thorough understanding of these interactions.

Overall, CLHC1 is a protein that has the potential to be a valuable drug target for the treatment of a variety of diseases. Its involvement in the regulation of miRNA levels, cellular signaling pathways, and growth and development make it an attractive target for the development of new therapeutic strategies. While further research is needed to fully understand the effects of CLHC1

Protein Name: Clathrin Heavy Chain Linker Domain Containing 1

The "CLHC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLHC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets